Definium director awarded RSUs and stock options
Definium Therapeutics director David W. Gryska received equity awards as part of his compensation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Definium Therapeutics director David W. Gryska received equity awards as part of his compensation. He was granted 4,666 restricted stock units, each representing one common share, and now holds 19,900 common shares directly after this grant. The filing also reports a grant of stock options for 19,188 common shares at an exercise price of $24.11 per share, expiring on June 10, 2036.
The restricted stock units and options each vest as to 1/12 of the underlying shares on every monthly anniversary of the grant date. If the company’s first annual meeting after the grant occurs before the first anniversary, any remaining unvested RSUs and options will vest immediately before that meeting, subject to his continued service.
Insider Trade Summary
Grant/Award: 23,854 shares
Grant/Award
2 txns
Insider
GRYSKA DAVID W
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 19,188 | $0.00 | $0.00 |
| Grant/Award | Common Shares | 4,666 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 19,188 contracts (Direct);
Common Shares — 19,900 shares (Direct)
Footnotes (2)
- F1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date.
- F2. The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date.
Key Figures
RSU grant: 4,666 units
Shares held after grant: 19,900 shares
Stock options granted: 19,188 options
+3 more
6 metrics
RSU grant
4,666 units
Restricted stock units granted to director on June 11, 2026
Shares held after grant
19,900 shares
Common shares directly held by director following RSU grant
Stock options granted
19,188 options
Stock Option (Right to Buy) granted on June 11, 2026
Option exercise price
$24.11 per share
Conversion or exercise price for 19,188 stock options
Option expiration
June 10, 2036
Expiration date of the granted stock options
Monthly vesting fraction
1/12 per month
RSUs and options vest 1/12 each monthly anniversary of grant
Key Terms
restricted stock units ("RSUs"), Stock Option (Right to Buy), vests and becomes exercisable, annual meeting
4 terms
restricted stock units ("RSUs") financial
"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with 19,188 underlying common shares and a $24.11 exercise price"
vests and becomes exercisable financial
"The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary"
annual meeting financial
"immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did DFTX director David W. Gryska report?
David W. Gryska reported receiving equity awards in Definium Therapeutics. He was granted 4,666 restricted stock units and stock options for 19,188 common shares as compensation, with no open-market buying or selling reported in this Form 4.
What stock options were granted to David W. Gryska by Definium Therapeutics (DFTX)?
He received stock options covering 19,188 common shares of Definium Therapeutics. These options have an exercise price of $24.11 per share and expire on June 10, 2036, providing long-term potential equity exposure if exercised.
How do David W. Gryska’s restricted stock units in DFTX vest?
The 4,666 restricted stock units vest in 12 equal monthly installments from the grant date. If the company’s next annual meeting occurs before the first anniversary, any unvested units vest immediately before that meeting, subject to his continued service.
What is the vesting schedule for David W. Gryska’s DFTX stock options?
The stock options for 19,188 common shares vest in 12 equal monthly installments from the grant date. If Definium Therapeutics’ next annual meeting occurs before the first anniversary, any unvested options vest immediately before that meeting, assuming he remains in service.
Was David W. Gryska’s DFTX Form 4 a purchase or a compensation grant?
The Form 4 reports compensation-related grants, not open-market purchases. David W. Gryska received restricted stock units and stock options at no cash cost per share on the grant date, categorized as grant or award acquisitions in the filing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates